
Medicine and Health
Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial
H. M. Colhoun, I. Lingvay, et al.
This study by authors including Helen M. Colhoun and Ildiko Lingvay reveals a promising potential of once-weekly semaglutide 2.4 mg to improve kidney outcomes in overweight and obese individuals without diabetes. With a significant reduction in the composite kidney endpoint, the findings offer a new perspective on kidney health in patients with cardiovascular disease.
Playback language: English
Related Publications
Explore these studies to deepen your understanding of the subject.